Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations

Lyudmila Bazhenova,Anna Minchom,Santiago Viteri,Joshua M Bauml,Sai-Hong Ignatius Ou,Shirish M Gadgeel,José Manuel Trigo,Daniel Backenroth,Tracy Li,Anil Londhe,Parthiv Mahadevia,Nicolas Girard

Lung Cancer（2021）

Cited 27|Views2

No score

Abstract

•Median rwOS was 16.2 months for EGFR exon20ins vs 25.5 months for cEGFR (p < 0.0001).•Median rwPFS was 2.9 months for EGFR exon20ins vs 10.5 months for cEGFR (p < 0001).•Platinum-based chemotherapy was most common 1L therapy for EGFR exon20ins (61.3%).•EGFR exon20ins has poor prognosis, with little benefit from EGFR TKI treatment.

Translated text

Key words

Non-small cell lung cancer,Advanced lung cancer,EGFR mutations,EGFR exon 20 insertions,Flatiron registry

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined